J. Am. Chem. Soc. 2001, 123, 4865-4866
4865
Design and Synthesis of a Novel DNA-DNA
Interstrand Adenine-Guanine Cross-Linking Agent
Qun Zhou,†,‡ Wenhu Duan,†,‡ Denise Simmons,§
Yuda Shayo,†,‡ Mary Ann Raymond,† Robert T. Dorr,†,‡ and
Laurence H. Hurley*,†,‡
Arizona Cancer Center, 1515 North Campbell AVenue
Tucson, Arizona 85724
College of Pharmacy, The UniVersity of Arizona
Tucson, Arizona 85721
College of Pharmacy, The UniVersity of Texas at Austin
Austin, Texas 78712
ReceiVed October 2, 2000
ReVised Manuscript ReceiVed March 29, 2001
DNA interstrand cross-linking agents that interact within the
minor groove have attracted considerable interest in the past few
years,1 and much progress has been made in the design and
synthesis of these compounds.2 These cross-linking agents belong
to two broad classes: natural products that cross-link 2-3 base
pairs apart1,3 and synthetic agents that cross-link 4-7 base pairs
apart.1,4 Both groups generally target either guanines (e.g.,
mitomycin C and DSB-120)1,3,4 or adenines (e.g., bizelesin).1,5
What is missing is the availability of minor groove DNA-DNA
interstrand cross-linking agents that alkylate guanines on one
strand and adenines on the opposite strand. This would provide
new agents capable of recognizing and binding to more extended
and mixed A‚T and G‚C sequence tracts of DNA to uniquely
define individual gene targets and hence exert biological specific-
ity. We report here the design and synthesis of the agent UTA-
6026, which contains two different alkylation moieties with the
potential to alkylate G or A.
Figure 1. Structures of (+)-CPI, DC-81, and target compound.
[1,4]benzodiazepine (P[1,4]B) family that is capable of covalently
reacting with the exocyclic 2-NH2 group of guanine7) were chosen
as the two monoalkylating subunits. By tethering them with a
suitable linker, a potential adenine-guanine interstrand cross-
linking agent could be synthesized. The linker was designed with
two objectives in mind. First, the indole was included to increase
the minor groove binding affinity without affecting the sequence
selectivity, which is primarily determined by the (+)-CPI alky-
lating subunit.8 Second, the flexible alkyl chain was chosen to
facilitate the isohelical accommodation of the P[1,4]B alkylating
subunit.2c The structure of the target compound is shown in Figure
1. To achieve the six-base-pair span, molecular modeling was
used to determine the alkyl chain length between the two
alkylating subunits. The modeling results (unpublished) show that
when n ) 3 (UTA-6026), the two units have an optimal chance
to alkylate the two desired sites, A* and G*, on opposite DNA
strands in sequence I to form the DNA-DNA interstrand cross-
link.
The strategy for the synthesis of compound UTA-6026 is shown
in Scheme 1. The main synthetic challenge is to form the active
cyclopropyl subunit in the (+)-CPI unit and the acid-sensitive
N10-C11 imine moiety in the P[1,4]B subunit in one molecule
at the same time. We used Thurston’s approach2e for synthesizing
the nucleophile-sensitive/acid-sensitive P[1,4]B analogues by
protecting the N10 with Fmoc and, after the remainder of the
molecule is assembled, removing the Fmoc group to form the
imine bond of the P[1,4]B subunit in the last step. Vanillic acid
(1), the starting material, was reacted with ethyl bromobutyrate,
followed by hydrolysis of the ester under basic conditions to give
compound 2. Nitration of 2 with nitric acid gave the nitro
compound 3. Selective esterification of 3 afforded the monoester
4, which was coupled with (2s)-(+)-pyrrolidine-2-carbaldehyde
diethyl thioacetal 12 to give 5. Reduction of 5 yielded the amino
compound 6. The amine was protected by the Fmoc group
followed by deprotection and cyclization of 7 with HgCl2/CaCO3
to give an Fmoc-protected P[1,4]B with an ether alkyl chain (8).
Hydrolysis of the methyl ester 8 under acidic conditions gave
the key intermediate acid 9.9a,b Compound 9 was coupled with
(+)-seco-CPI-indole 139c,d,e (which was converted from N-mesyl-
We chose a DNA sequence (sequence I in Figure 1) containing
an adenine and guanine six base pairs apart on opposite strands
as the potential DNA cross-linking target template. To achieve
the cross-linking, (+)-cyclopropapyrroloindole [(+)-CPI] (the
DNA-DNA alkylating moiety of (+)-CC-1065 that selectively
alkylates N3 of adenine6) and DC-81 (one member of the pyrrolo-
† Arizona Cancer Center.
‡ The University of Arizona.
§ The University of Texas at Austin.
(1) For a comprehensive review of DNA cross-linkers, see: Rajski, S. R.;
Williams, R. M. Chem. ReV. 1998, 98, 2723.
(2) (a) Mitchell, M. A.; Johnson, P. D.; Williams, M. G.; Aristoff, P. A. J.
Am. Chem. Soc. 1989, 111, 6428. (b) Mitchell, M. A.; Kelly, R. C.; Wicnienski,
N. A.; Hatzenbuhler, N. T.; Williams, M. G.; Petzold, G. L.; Slightom, J. L.;
Siemieniak, D. R. J. Am. Chem. Soc. 1991, 113, 8994. (c) Bose, D. S.;
Thompson, A. S.; Ching, J. S.; Hartley, J. A.; Berardini, M. D.; Jenkins, T.
C.; Neidle, S.; Hurley, L. H.; Thurston, D. E. J. Am. Chem. Soc. 1992, 114,
4939. (d) Thurston, D. E.; Bose, D. S.; Howard, P.; Jenkins, T. C.; Leoni, A.;
Beraldi, P. G.; Guiotto, A.; Cacciari, B.; Kelland, L. R.; Floppe, M. P.; Rault,
S. J. Med. Chem. 1999, 42, 1951. (e) Wilson, S. C.; Howard, P. W.; Forrow,
S. M.; Hartley, J. A.; Adams, L. J.; Jenkins, T. C.; Kelland, L. R.; Thurston,
D. E. J. Med. Chem. 1999, 42, 4028. (f) Mountzouris, J. A.; Wang, J. J.;
Thurston, D. E.; Hurley, L. H. J. Med. Chem. 1994, 37, 3132. (g) Gregson,
S. J.; Howard, P. W.; Jenkins, T. C.; Kelland, L. R.; Thurston, D. E. Chem.
Commun. 1999, 9, 797.
(3) (a) Norman, D.; Live, D.; Sastry, M.; Lipman, R.; Hingerty, B. E.;
Tomasz, M.; Broyde, S.; Patel, D. J. Biochemistry 1990, 29, 2861. (b) Tomasz,
M.; Palom, Y. Pharmcol. Ther. 1997, 76, 73.
(4) (a) Hurley, L. H. The Minor Groove Covalent Reactive Drugs
Anthramycin and CC-1065 and Their Interstrand Cross-linking Derivatives.
In DNA Adducts of Carcinogenic and Mutagenic Agents: Chemistry,
Identification, and Biological Significance; IARC Scientific Publications Series,
1993; pp 295-312. (b) Mountzouris, J. A.; Hurley, L. H. Small Molecule-
DNA Interactions. In Bioorganic Chemistry: Nucleic Acids; Oxford University
Press: New York, 1996; pp 288-323.
(5) (a) Ding, Z. M.; Hurley, L. H. Anti-Cancer Drug Des. 1991, 6, 427.
(b) Sun, D.; Hurley, L. H. J. Am. Chem. Soc. 1993, 115, 5925. (c) Seaman
F.; Hurley, L. H. Biochemistry 1993, 32, 12577. (d) Seaman, F. C.; Chu, J.;
Hurley, L. H. J. Am. Chem. Soc. 1996, 118, 5383. (e) Woynarowski, J. M.;
McHugh, M. M.; Gawron, L. S.; Beerman, T. A. Biochemistry 1995, 34, 13042.
(6) Hurley, L. H.; Reynolds, V. L.; Swenson, D. H.; Petzold, G. L.; Scahill,
T. A. Science 1984, 226, 843.
(7) Hurley, L. H.; Petrusek, R. L. Nature 1979, 282, 529.
(8) Hurley, L. H.; Lee, C.-S.; McGovren, J. P.; Mitchell, M.; Warpehoski,
M. A.; Kelly, R. C.; Aristoff, P. A. Biochemistry 1988, 27, 3886-3892.
10.1021/ja005658r CCC: $20.00 © 2001 American Chemical Society
Published on Web 05/01/2001